- Previous Close
92.00 - Open
92.50 - Bid 93.00 x 60000
- Ask 94.50 x 60000
- Day's Range
92.00 - 94.00 - 52 Week Range
62.00 - 105.00 - Volume
100 - Avg. Volume
218 - Market Cap (intraday)
140.855B - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
81.03 - EPS (TTM)
1.16 - Earnings Date Apr 22, 2025 - Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
www.bostonscientific.comRecent News: BSX.F
View MorePerformance Overview: BSX.F
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BSX.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BSX.F
View MoreValuation Measures
Market Cap
137.86B
Enterprise Value
147.78B
Trailing P/E
79.66
Forward P/E
34.97
PEG Ratio (5yr expected)
1.96
Price/Sales (ttm)
8.83
Price/Book (mrq)
6.77
Enterprise Value/Revenue
9.55
Enterprise Value/EBITDA
41.48
Financial Highlights
Profitability and Income Statement
Profit Margin
11.07%
Return on Assets (ttm)
5.03%
Return on Equity (ttm)
8.89%
Revenue (ttm)
16.75B
Net Income Avi to Common (ttm)
1.85B
Diluted EPS (ttm)
1.16
Balance Sheet and Cash Flow
Total Cash (mrq)
414M
Total Debt/Equity (mrq)
51.03%
Levered Free Cash Flow (ttm)
1.81B